Glucagon-like peptide-2 (GLP-2) analogs are a relatively new class of drugs that have improved intestinal adaptation in patients with SBS-associated intestinal failure with demonstrable safety profile [45]. The gene discussed is GCG; the disease is macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.